Firebrick Pharma Limited (AU:FRE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited launched their Nasodine nasal spray in the US and Singapore, marking a significant expansion of their product availability. Despite initial limited sales in the US due to seasonal factors, expectations are high for growth with the upcoming winter season. The company also secured a new patent in South Africa and raised $800,000 through a share placement to support Nasodine’s launch and working capital needs.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.